Status:
COMPLETED
Vaginal Isonicotinic Acid Hydrazide Administration Prior to Intrauterine Device Insertion
Lead Sponsor:
Aswan University Hospital
Conditions:
IUCD Complication
Eligibility:
FEMALE
18-25 years
Phase:
PHASE4
Brief Summary
To investigate whether vaginal isonicotinic acid hydrazide administered before the levonorgestrel-releasing intrauterine system insertion reduces IUD insertion pain and difficulty in insertion in adol...
Detailed Description
Long-acting reversible contraception methods are highly effective methods for reduction of the unplanned pregnancy rate worldwide. The intrauterine device is a single procedure that provides reliable,...
Eligibility Criteria
Inclusion
- nulliparous adolescent and young women requesting levonorgestrel-releasing intrauterine device
Exclusion
- pregnancy and
- contraindication or allergy to or contraindication to IUD insertion,
- chronic pelvic pain,
- pelvic inflammatory disease,
- analgesic intake 24 hours prior to IUD insertion.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2021
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04500015
Start Date
September 1 2020
End Date
August 30 2021
Last Update
September 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University Hospital
Aswān, Egypt, 81528